Biomarkers for alzheimer's disease: Showing the way or leading us astray?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a "presymptomatic" stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine "go-no go" decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

Original languageEnglish (US)
Title of host publicationAlzheimer's Disease
Subtitle of host publicationAdvances for a New Century
PublisherIOS Press
Pages371-376
Number of pages6
ISBN (Electronic)9781614991540
ISBN (Print)9781614991533
DOIs
StatePublished - Feb 15 2013

Fingerprint

Alzheimer Disease
Biomarkers
Asymptomatic Diseases
Patient Selection
Clinical Trials
Pharmaceutical Preparations
Therapeutics

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Clinical trials

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Quinn, J. (2013). Biomarkers for alzheimer's disease: Showing the way or leading us astray? In Alzheimer's Disease: Advances for a New Century (pp. 371-376). IOS Press. https://doi.org/10.3233/978-1-61499-154-0-371

Biomarkers for alzheimer's disease : Showing the way or leading us astray? / Quinn, Joseph.

Alzheimer's Disease: Advances for a New Century. IOS Press, 2013. p. 371-376.

Research output: Chapter in Book/Report/Conference proceedingChapter

Quinn, J 2013, Biomarkers for alzheimer's disease: Showing the way or leading us astray? in Alzheimer's Disease: Advances for a New Century. IOS Press, pp. 371-376. https://doi.org/10.3233/978-1-61499-154-0-371
Quinn, Joseph. / Biomarkers for alzheimer's disease : Showing the way or leading us astray?. Alzheimer's Disease: Advances for a New Century. IOS Press, 2013. pp. 371-376
@inbook{4c68b0cc22e3429594afd6b2a662e104,
title = "Biomarkers for alzheimer's disease: Showing the way or leading us astray?",
abstract = "The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a {"}presymptomatic{"} stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine {"}go-no go{"} decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.",
keywords = "Alzheimer's disease, Biomarkers, Clinical trials",
author = "Joseph Quinn",
year = "2013",
month = "2",
day = "15",
doi = "10.3233/978-1-61499-154-0-371",
language = "English (US)",
isbn = "9781614991533",
pages = "371--376",
booktitle = "Alzheimer's Disease",
publisher = "IOS Press",

}

TY - CHAP

T1 - Biomarkers for alzheimer's disease

T2 - Showing the way or leading us astray?

AU - Quinn, Joseph

PY - 2013/2/15

Y1 - 2013/2/15

N2 - The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a "presymptomatic" stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine "go-no go" decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

AB - The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a "presymptomatic" stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine "go-no go" decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

KW - Alzheimer's disease

KW - Biomarkers

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=85028291424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028291424&partnerID=8YFLogxK

U2 - 10.3233/978-1-61499-154-0-371

DO - 10.3233/978-1-61499-154-0-371

M3 - Chapter

AN - SCOPUS:85028291424

SN - 9781614991533

SP - 371

EP - 376

BT - Alzheimer's Disease

PB - IOS Press

ER -